Biomedical Engineering Reference
In-Depth Information
62. Nilsson F, Tarli L, Viti F, Neri D (2000) The use of phage display for the development of
tumour targeting agents. Adv Drug Deliv Rev 43:165-196
63. Ivanenkov VV, Felici F, Menon AG (1999) Uptake and intracellular fate of phage display vec-
tors in mammalian cells. Biochim Biophys Acta 1448:450-462
64. Stacey A, Palasek ZJ, Cox ZJ, Collins JM (2007) Limiting racemization and aspartimide for-
mation in microwave-enhanced Fmoc solid phase peptide synthesis. J Pept Sci 13:143-148
65. Skerra A (2000) Engineered protein scaffolds for molecular recognition. J Mol Recognit
13:167-187
66. Wurch T, Lowe P, Caussanel V, Bes C, Beck A, Corvaia N (2008) Development of novel pro-
tein scaffolds as alternatives to whole antibodies for imaging and therapy: status on discovery
research and clinical validation. Curr Pharm Biotechnol 9:502-509
67. Duncan R, Izzo L (2005) Dendrimer biocompatibility and doxicity. Adv Drug Deliv Rev
57:2215-2237
68. Esfand T (2001) Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery
and biomedical applications. Drug Discov Today 6:427-436
69. Hobson LJ, Feast WJ (1999) Poly(amidoamine) hyperbranched systems: synthesis, structure
and characterization. Polymer 40:1279-1297
70. Wells NJ, Basso A, Bradley M (1999) Solid-phase dendrimer synthesis. Biopolymers
47:381-396
71. Al Jamal KT, Ramaswamy C, Florence AT (2005) Supramolecular structures from dendrons
and dendrimers. Adv Drug Deliv Rev 57:2238-2270
72. Tang MX, Redemann CT, Szoka FC (1996) In vitro gene delivery by degraded polyamidoam-
ine dendrimers. Bioconjug Chem 7:703-714
73. Monaghan S (2001) Solid-phase synthesis of peptide-dendrimer conjugates for an investiga-
tion of integrin binding. ARKIVOC 46-53
74. Wijelath E, Namekata M, Murray J, Furuyashiki M, Zhang S, Coan D, Wakao M, Harris RB,
Suda Y, Wang LM (2010) Multiple mechanisms for exogenous heparin modulation of vascular
endothelial growth factor activity. J Cell Biochem 111:461-468
Search WWH ::
Custom Search